Showing 1831-1840 of 2657 results for "".
- Celltrion Receives FDA Approval for Eylea Biosimilar Eydenzelthttps://modernod.com/news/celltrion-receives-fda-approval-for-eylea-biosimilar-eydenzelt/2484171/The FDA has approved Celltrion's Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea (aflibercept), for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO)
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- Kala Halts Development of Investigational PCED Eye Drop After Phase 2b Trial Fails to Meet Endpointshttps://modernod.com/news/kala-halts-development-of-investigational-pced-eye-drop-after-phase-2b-trial-fails-to-meet-endpoints/2484150/Kala Bio said it is ceasing development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform after its phase 2b trial evaluating KPI-012 in persistent corneal epithelial defect (PCED) did not meet its primary or secondary efficacy endpoints.
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to
- FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for Wet AMDhttps://modernod.com/news/fda-grants-fast-track-designation-to-sanofis-investigational-gene-therapy-for-wet-amd/2484142/The FDA has granted fast track designation to Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA&rs
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Technologyhttps://modernod.com/news/vsy-biotechnology-launches-enova-hydrophobic-iols-with-rotaryjet-technology/2482932/VSY Biotechnology has launched the Enova Hydrophobic IOLs, with the company's Rotaryjet Preloaded Delivery System. This technology is designed to provide ophthalmic surgeons with a safer, more efficient, and user-friendly solution for lens implantation. The patented Rotary
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and